碘奥酮 | 300-37-8

• 物质功能分类: 原料药 - 诊断用药 - 影象检查用药
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 碘奥酮
• 英文名称: Uriodone
• 英文别名: Diodon；3,5-diiodo-4-pyridone-N-acetic acid diethanolamine salt；diatrast；Diodone；2-(3,5-diiodo-4-oxopyridin-1-yl)acetic acid;2-(2-hydroxyethylamino)ethanol
• CAS: 300-37-8
• 化学式: C₄H₁₁NO₂*C₇H₅I₂NO₃
• 分子量: 510.067
• InChiKey: RERHJVNYJKZHLJ-UHFFFAOYSA-N

物化性质

• 熔点：
  245-249°

计算性质

• 辛醇/水分配系数(LogP)：
  -2.66
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  118
• 氢给体数：
  3
• 氢受体数：
  6

安全信息

• 海关编码：
  2933990090

文献信息

• [EN] PHOTORESPONSIVE NUTLIN DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE NUTLINE PHOTOSENSIBLES ET LEURS UTILISATIONS
  申请人：UNIV GRONINGEN

  公开号：WO2020071911A1

  公开（公告）日：2020-04-09

  The invention relates to the field of medicine and medicinal chemistry, more in particular to the design, manufacture and use of anti-cancer drugs that can be activated by an external stimulus that can be applied in a spatiotemporal fashion. Provided herein is a compound having the chemical structure or a pharmaceutically acceptable salt thereof.

  这项发明涉及医学和药物化学领域，更具体地涉及设计、制造和使用可以通过外部刺激激活的抗癌药物，该外部刺激可以以时空方式应用。本文提供了具有该化学结构或其药用可接受盐的化合物。
• Polyesteramide platform for site specific drug delivery
  申请人：Kleiner W. Lothar

  公开号：US20070243256A1

  公开（公告）日：2007-10-18

  A therapeutic agent delivery system formed of a specific type of poly(ester amide) (PEA), a therapeutic agent, and a water miscible solvent is described herein. A method of delivering the therapeutic agent delivery system by delivering the therapeutic agent delivery system formed of a PEA polymer, a therapeutic agent, and a water miscible solvent to a physiological environment and separating the phase of the therapeutic agent delivery system to form a membrane from the polymer to contain the therapeutic agent within the physiological environment is also described. Additionally disclosed is a kit including a syringe and a therapeutic agent delivery system within the syringe.

  本文描述了一种由特定类型的聚（酯酰胺）（PEA）、治疗剂和水溶性溶剂组成的治疗剂传递系统。还描述了一种通过将由PEA聚合物、治疗剂和水溶性溶剂组成的治疗剂传递系统传递到生理环境中，并将治疗剂传递系统的相分离以形成膜，从而在生理环境中包含治疗剂的方法。此外，还公开了一种包括注射器和注射器内的治疗剂传递系统的套件。
• [EN] Novel 7-Dehydrocholesterol Derivatives and Methods Using Same<br/>[FR] NOUVEUX DÉRIVÉS DE 7-DÉSHYDROCHOLESTÉROL ET PROCÉDÉS LES UTILISANT
  申请人：WOMEN & INFANTS HOSPITAL OF RHODE ISLAND

  公开号：WO2015157262A1

  公开（公告）日：2015-10-15

  The present invention provides, in certain aspects, novel 7-dehydrocholesterol (7DHC) derivatives that are useful in treating or preventing cancer, as well as in treating or preventing uncontrolled angiogenesis, in a subject. In certain embodiments of the present invention, the subject is a human. In other aspects, the present invention provides a method of preparing compounds of the invention, or a salt or solvate thereof.

  本发明在某些方面提供了新颖的7-去氢胆固醇（7DHC）衍生物，这些衍生物在治疗或预防癌症以及治疗或预防受试者中的不受控制的血管生成方面是有用的。在本发明的某些实施例中，受试者是人类。在其他方面，本发明提供了制备本发明化合物的方法，或其盐或溶剂。
• Novel kinase inhibitors
  申请人：Thormann Michael

  公开号：US20120329785A1

  公开（公告）日：2012-12-27

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases.

  本发明涉及式（I）的新型化合物，这些化合物能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体。这些化合物可用于治疗各种疾病。
• Method of preparing liposomes and products produced thereby
  申请人：E.R. Squibb & Sons, Inc.

  公开号：EP0119020A2

  公开（公告）日：1984-09-19

  A method is provided for preparing a stable liposome precursors in the form of a particulate carrier materials coated with thin films of liposome components, which method includes the steps of dissolving at least one liposome-forming amphipathic lipid, optionally, at least one biologically active compound, and, optionally, at least one adjuvant in a suitable solvent and employing the resulting solution to coat a suitable particulate carrier material which is substantially insoluble in the above-mentioned solvent, to form thin films of liposome components thereon. Upon exposing the coated carrier material to water, the thin films of liposome components hydrate. If the carrier material is water-insoluble, it is then separated e.g. by filtration or centrifuging.

  本发明提供了一种制备稳定的脂质体前体的方法，其形式为涂有脂质体成分薄膜的微粒载体材料，该方法包括以下步骤：将至少一种脂质体形成两性脂质、可选的至少一种生物活性化合物和可选的至少一种佐剂溶解在一种合适的溶剂中，并用所得溶液涂覆在基本上不溶于上述溶剂的合适的微粒载体材料上，以在其上形成脂质体成分薄膜。将涂覆的载体材料置于水中，脂质体成分薄膜就会水合。如果载体材料不溶于水，则通过过滤或离心等方法将其分离。